Pharmafile Logo
Pharmafocus logo
Advanced Search

Novo Nordisk

Showing 15 posts of 177 posts found.

novo_nordisk_flag

Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

January 17, 2020
Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …

News

Novo Nordisk to offer US patient’s in immediate need free insulin

January 3, 2020
Medical Communications Novo, Novo Nordisk, Type 1 diabetes, diabetes, insulin, type 2 diabetes

Novo Nordisk said it would offer free, one-time supply of insulin to those in need, amidst rising insulin prices. Novo …

News

Novo Nordisk opens first Pharmatech branch office in Singapore

October 22, 2019
Manufacturing and Production Novo Nordisk, Singapore, pharma

Novo Nordisk has celebrated the launch of a new Pharmatech A/S branch office based in Singapore at a grand opening …

News
novo_flag

Novo’s Tresiba lowers hypoglycaemia risk compared to insulin glargine in type 2 diabetes

September 20, 2019
Medical Communications, Research and Development Novo Nordisk, Tresiba, diabetes, pharma

Novo Nordisk has unveiled new data for Tresiba (insulin degludec) at the 55th Annual Meeting of the European Association for …

News

Novo Nordisk set to launch price cut for insulin drug NovoLog after harsh criticism over prices in the US

September 9, 2019
Sales and Marketing Novo Nordisk, NovoLog, insulin

Danish drug maker Novo Nordisk has said it will offer a generic version of NovoLog (insulin aspart) at a price …

News
novo_flag

European approval for Novo’s Esperoct in haemophilia A

June 21, 2019
Medical Communications, Sales and Marketing Esperoct, Novo Nordisk, haemophilia, pharma

The European Commission has awarded approval to Novo Nordisk’s extended half-life factor VIII therapy Esperoct (turoctocog alfa pegol, N8-GP) for …

News
novo_flag

FDA approves Novo Nordisk’s Victoza for children with type 2 diabetes

June 18, 2019
Manufacturing and Production GLP-1, Novo Nordisk, Victoza, diabetes, liraglutide

The FDA has approved Novo Nordisk’s Victoza (liraglutide) for paediatric patients aged 10 years and older with type 2 diabetes. …

News

Novo Nordisk’s oral diabetes drug safe and effective

June 12, 2019
Research and Development GLP-1, Novo Nordisk, diabetes, pharma, samgalutide

Novo Nordisk’s oral diabetes drug semaglutide is safe for those at high risk of cardiovascular complications, according to the results …

News

Novo’s oral semaglutide tops Jardiance and Victoza in two type 2 diabetes trials

June 10, 2019
Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has taken the opportunity at the American Diabetes Association (ADA) 79th Scientific Sessions to pull back the curtain …

News
novo_flag

Novo Holdings invests £53.5 million into Oxford Biomedica

May 30, 2019
Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus

Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …

News

Working Life: Dr Todd Hobbs, Vice President and Chief Medical Officer, Novo Nordisk

April 24, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Working Life, feature, pharma

Novo Nordisk’s VP and CMO discusses his leap from family medicine into the pharma industry, his biggest achievements, and how …

Feature
novo_nordisk_flag

Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes

March 26, 2019
Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

January 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Netherlands, Novo Nordisk, Roche, astra zeneca, prcing, sequiris, top 10, uk politics

Job switches were the theme of this week as AstraZeneca lost three, high levels executives to biotechs amid a restructuring …

News
novo_flag

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for eleven markets in Asia Pacific

January 16, 2019
Manufacturing and Production, Medical Communications, Research and Development DKSH, Novo Nordisk, pharma

DKSH’s Business Unit Performance Materials, a leading ingredients and specialty chemicals distributor, will distribute Novo Nordisk Pharmatech’s pharmaceutical grade compounds …

News
novo_nordisk_flag

Novo Nordisk’s semaglutide meets primary endpoint of reducing cardiovascular events at Phase 3

November 26, 2018
Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide

Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023